Related Experiment Video

Updated: Jul 20, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Acute and maintenance treatment of chronic depression

D L Dunner1

  • 1Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105-6099, USA. ddunner@u.washington.edu

The Journal of Clinical Psychiatry
|April 20, 2001
PubMed

Insights

Chronic depression, including dysthymic disorder, is common and often undertreated. Effective management requires longer treatment durations and potentially higher medication doses compared to acute depression.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Neuroscience

Background:

  • Chronic depression affects one-third of all depression cases.
  • These conditions are frequently underrecognized and undertreated.
  • Understanding chronic depression subtypes is crucial for effective intervention.

Purpose of the Study:

  • To define various types of chronic depression.
  • To review current and emerging treatment strategies.
  • To highlight the importance of tailored treatment approaches.

Main Methods:

  • Literature review of chronic depression subtypes.
  • Analysis of treatment efficacy for chronic mood disorders.
  • Synthesis of findings on pharmacotherapy and psychotherapy combinations.

Main Results:

  • Chronic depression encompasses dysthymic disorder, double depression, chronic major depression, and major depression in incomplete remission.
  • Treatment principles involve extended duration and potentially higher doses than for acute depression.
  • Psychosocial disability and symptom severity can be improved with appropriate interventions.

Conclusions:

  • Chronic depression necessitates distinct treatment strategies.
  • Combination therapy (psychotherapy and pharmacotherapy) shows promise for chronic mood disorders.
  • Addressing chronic depression can significantly improve patient outcomes and functioning.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...